Literature DB >> 20005858

Cellular and humoral responses induced by Leishmania histone H2B and its divergent and conserved parts in cutaneous and visceral leishmaniasis patients, respectively.

A Meddeb-Garnaoui1, A Toumi, H Ghelis, M Mahjoub, H Louzir, M Chenik.   

Abstract

Leishmania histone H2B has been reported to be a promising candidate for both vaccination and serodiagnosis. We evaluated the cellular immune responses induced by H2B and its divergent amino-terminal (H2B-N) and conserved carboxy-terminal (H2B-C) regions in individuals with a history of Localized Cutaneous Leishmaniasis (LCL) due to Leishmania (L.) major. H2B induced significantly high PBMC proliferation and IFNgamma levels in LCL individuals whereas significantly lower proliferation and IFNgamma levels were observed with the divergent part of the protein. All proteins induced IL10 in LCL and healthy individuals. We also evaluated the humoral responses induced by these proteins in patients with Mediterranean Visceral Leishmaniasis (MVL) due to L. infantum. H2B and H2B-N were highly recognized by MVL sera. Our results show that the entire H2B protein is more efficient than its amino- and carboxy-terminal regions in inducing a dominant Th1 profile in cured LCL subjects and suggest that this protein may constitute a potential vaccine against leishmaniasis. Furthermore, H2B and H2B-N are interesting antigens for serodiagnosis of MVL. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20005858     DOI: 10.1016/j.vaccine.2009.11.075

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Evaluation of an enzyme-linked immunosorbent assay based on crude Leishmania histone proteins for serodiagnosis of human infantile visceral leishmaniasis.

Authors:  Sami Lakhal; Salima Mekki; Imène Ben-Abda; Mohamed Mousli; Fethi Amri; Karim Aoun; Aïda Bouratbine
Journal:  Clin Vaccine Immunol       Date:  2012-07-18

Review 2.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

3.  Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites.

Authors:  Angamuthu Selvapandiyan; Ranadhir Dey; Sreenivas Gannavaram; Ines Lakhal-Naouar; Robert Duncan; Poonam Salotra; Hira L Nakhasi
Journal:  J Trop Med       Date:  2011-09-06

4.  Vaccine Development Against Leishmania donovani.

Authors:  Amrita Das; Nahid Ali
Journal:  Front Immunol       Date:  2012-05-15       Impact factor: 7.561

5.  Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.

Authors:  Laura Ramirez; Laura Corvo; Mariana C Duarte; Miguel A Chávez-Fumagalli; Diogo G Valadares; Diego M Santos; Camila I de Oliveira; Marta R Escutia; Carlos Alonso; Pedro Bonay; Carlos A P Tavares; Eduardo A F Coelho; Manuel Soto
Journal:  Parasit Vectors       Date:  2014-01-02       Impact factor: 3.876

Review 6.  Possibilities and challenges for developing a successful vaccine for leishmaniasis.

Authors:  Saumya Srivastava; Prem Shankar; Jyotsna Mishra; Sarman Singh
Journal:  Parasit Vectors       Date:  2016-05-12       Impact factor: 3.876

7.  Leishmania major large RAB GTPase is highly immunogenic in individuals immune to cutaneous and visceral leishmaniasis.

Authors:  Rym Chamakh-Ayari; Mehdi Chenik; Ahmed Sahbi Chakroun; Narges Bahi-Jaber; Karim Aoun; Amel Meddeb-Garnaoui
Journal:  Parasit Vectors       Date:  2017-04-17       Impact factor: 3.876

8.  Vaccination with L. infantum chagasi nucleosomal histones confers protection against new world cutaneous leishmaniasis caused by Leishmania braziliensis.

Authors:  Marcia W Carneiro; Diego M Santos; Kiyoshi F Fukutani; Jorge Clarencio; Jose Carlos Miranda; Claudia Brodskyn; Aldina Barral; Manoel Barral-Netto; Manuel Soto; Camila I de Oliveira
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

9.  Towards a more precise serological diagnosis of human tegumentary leishmaniasis using Leishmania recombinant proteins.

Authors:  Ana Paula Souza; Manuel Soto; Jackson M L Costa; Viviane S Boaventura; Camila I de Oliveira; Juqueline R Cristal; Manoel Barral-Netto; Aldina Barral
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

10.  Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice.

Authors:  Manuel Soto; Laura Corvo; Esther Garde; Laura Ramírez; Virginia Iniesta; Pedro Bonay; Carlos Gómez-Nieto; Víctor M González; M Elena Martín; Carlos Alonso; Eduardo A F Coelho; Aldina Barral; Manoel Barral-Netto; Salvador Iborra
Journal:  PLoS Negl Trop Dis       Date:  2015-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.